Skip to main content
FDA clears expanded claims for Cepheid's molecular test
5/16/2018

Cepheid obtained clearance from the FDA for expanded claims for its Xpert Carba-R, which is designed to detect carbapenemase-producing gram-negative bacteria. The clearance enables the molecular test to be used for analyzing perirectal swab specimens, enabling test results to be used for therapeutic strategies for pure colonies.

Full Story: